Aminocaproic acid (Aminocaproic acid)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceAminocaproic acidAminocaproic acid
Similar drugsTo uncover
  • Aminocaproic acid
    solution d / infusion 
    ALIUM PFK, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
    PLANT MEDSINTEZ, LLC     Russia
  • Aminocaproic acid
    solution d / infusion 
    EAST-FARM, CJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    Promomed Rus, Open Company     Russia
  • Aminocaproic acid
    solution d / infusion 
    NESVIZH FACTORY OF MEDICAL PREPARATIONS, RUP     Republic of Belarus
  • Aminocaproic acid
    solution d / infusion 
    FIRM MEDPOLIMER, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    ESKOM NPK, OAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    DALHIMFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    KRASFARMA, JSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    MOSHIMFARM PREPARATES them. N.А.Semashko, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    MOSFARM, OJSC     Russia
  • Aminocaproic acid
    solution d / infusion 
    BIOSINTEZ, PAO     Russia
  • Aminocaproic acid
    solution d / infusion 
    Avexima Sibir, OOO     Russia
  • Aminocaproic acid-SOLOfarm
    solution d / infusion 
    GROTEKS, LLC     Russia
    • Dosage form: & nbspsolution for infusions
    Composition:

    Active substance: aminocaproic acid 5.0 g; Excipients: sodium chloride - 0.9 g, water for injection - up to 100 ml.

    Description:

    Transparent colorless liquid.

    Pharmacotherapeutic group:Hemostatic agent, inhibitor of fibrinolysis
    ATX: & nbsp

    B.02.A.A.01   Aminocaproic acid

    Pharmacodynamics:

    Aminocaproic acid refers to synthetic analogues of lysine. It inhibits fibrinolysis, competing saturating lysine-binding receptors, through which plasminogen (plasmin) binds to fibrinogen (fibrin). The drug also inhibits biogenic polypeptides-kinin (inhibits the activating action of streptokinase, urokinase, tissue kinases for fibrinolysis), neutralizes the effects of kallikrein, trypsin and hyaluronidase, reduces the permeability of capillaries. Amino-caproic acid has an antiallergic effect, enhances detoxifying function of the liver, inhibits antibody formation.

    Pharmacokinetics:

    With intravenous administration, the effect is manifested after 15-20 minutes. The drug is quickly excreted by the kidneys - 40% - 60% of the administered amount after 4 hours is excreted in the urine unchanged. If the excretory function of the kidneys is violated, the concentration of aminocaproic acid in the blood increases significantly.

    Indications:

    Bleeding (hyperfibrinolysis, hypo- and afibrinogenemia). Bleeding during surgical interventions on organs rich in fibrinolysis activators (brain and spinal cord, lungs, heart, vessels, thyroid and pancreas, prostate gland). Diseases of internal organs with hemorrhagic syndrome. Premature detachment of the placenta, prolonged retention in the uterine cavity of the dead fetus, complicated abortion. To prevent secondary hypofibrinogenemia in massive transfusions of canned blood.

    Contraindications:

    Hypersensitivity to the drug, a tendency to thrombosis and thromboembolic diseases, hypercoagulation (thrombosis, thromboembolism), coagulopathy due to diffuse intravascular coagulation, kidney disease with impaired excretory function, hematuria, pregnancy, cerebral circulation disorders.

    Carefully:

    Heart diseases, bleeding from the upper urinary tract unidentified etiology, liver failure, chronic renal failure, arterial hypotension, valvular heart disease.

    Pregnancy and lactation:

    The use of the drug is acceptable if the expected benefit for the mother exceeds the potential risk to the fetus and the baby.

    Dosing and Administration:

    Aminocaproic acid is administered intravenously. The daily dosage for adults is 5-30, with the need to achieve a rapid effect (acute gipofibrinogenemia) is administered intravenously to a 100 mL sterile 5% solution of sodium chloride isotonic solution at a rate of 50-60 drops per minute. During the first hour, a dose of 4-5 g is administered, in the case of continuing bleeding to its full stop - 1 g every hour for not more than 8 hours. If it is necessary to introduce 5 % acid solution of aminocaproic acid is repeated.

    Children, at the rate of 100 mg / kg body weight in the first hour, then 33 mg / kg / h, the maximum daily dose of -18 g / m2 surface of the body.

    The duration of therapy is 3-14 days.

    Side effects:

    Dizziness, tinnitus, headache, nausea, diarrhea, inflammation of the upper respiratory tract, nasal congestion, skin rash, orthostatic hypotension, convulsions, acute renal failure, subendocardial haemorrhage, rhabdomyolysis, lowering blood pressure.

    Overdose:

    A sharp decrease in fibrinolytic activity of the blood. Severe side effects symptoms: dizziness, nausea, diarrhea, skin rash, orthostatic hypotension, convulsions, headache, nasal congestion, acute renal failure, rhabdomyolysis, myoglobinuria.

    Treatment. In case of an overdose, the drug is discontinued and symptomatic therapy is performed.

    Interaction:

    You can combine with the introduction of hydrolysers, a solution of glucose (dextrose), anti-shock solutions. In acute fibrinolysis, fibrinogen should additionally be administered in an average daily dose of 2-4 g (maximum dose of 8 g).

    Decrease in efficacy with simultaneous reception of anticoagulants of direct and indirect action, antiplatelet agents.

    Special instructions:The purpose of the drug requires checking the fibrinolytic activity of blood and the concentration of fibrinogen in the blood. With intravenous administration, coagulogram monitoring is necessary, especially in coronary heart disease, after myocardial infarction, in pathological processes in the liver.
    Effect on the ability to drive transp.cf. and fur:

    Data are not available due to the exclusive use of the drug in a hospital setting.

    Form release / dosage:

    Solution for infusions 50 mg / ml.

    Packaging:

    100, 200 ml in glass bottles for blood, infusion and transfusion preparations with a capacity of 100, 250 ml respectively, sealed with rubber stoppers and crimped with aluminum caps.

    Each bottle, together with instructions for use, is placed in a pack of cardboard.

    35 bottles with a capacity of 100 ml, 24, 28 bottles with a capacity of 250 ml are placed in boxes of corrugated paperboard with the application instructions for the appropriate number of bottles (for hospitals).

    100, 200 ml in bags of a film of multilayer polymeric M312A Nexcel™.

    56 bags of 100 ml, 24, 28 packages of 200 ml are placed in boxes of cardboard corrugated together with instructions for use in an amount corresponding to the number of packages (for hospitals).
    Storage conditions:

    In the dark place at a temperature of no higher than 25 ° C. Store in inaccessible to children place.

    Shelf life:

    3 years.

    After the expiration date indicated on the package, the drug should not be used.

    Terms of leave from pharmacies:On prescription
    Registration number:LS-002292
    Date of registration:16.12.2011 / 31.05.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:Promomed Rus, Open CompanyPromomed Rus, Open Company Russia
    Manufacturer: & nbsp
    Information update date: & nbsp07.08.2017
    Illustrated instructions
      Instructions
      Up